← Eichor
Condition: Advanced Hepatocellular Carcinoma Hcc Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Hepatocellular Carcinoma Hcc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepato
Phase 2 · 4 location(s) · Riboscience, LLC. · NCT07175441A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves T
Phase 1 · 11 location(s) · AbbVie · NCT06487559Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Phase 3 · 11 location(s) · Polaris Group · NCT05317819Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies
Phase N/A · 1 location(s) · Zhongda Hospital · NCT06607120HAIC Compared With TACE in Huge Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06641713Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07099274Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
NA · 1 location(s) · Tanta University · NCT06961526Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Phase 1/Phase 2 · 7 location(s) · OriCell Therapeutics Co., Ltd. · NCT05652920Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
NA · 1 location(s) · Shenzhen University General Hospital · NCT05620706Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06323382Amplitude-modulated Radiofrequency Electromagnetic Field Treatment for Advanced Hepatocellular Carcinoma (Immune-RF)
NA · 1 location(s) · Charite University, Berlin, Germany · NCT06821958A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
Phase 1 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07478302Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Phase 2 · 1 location(s) · Humanity & Health Medical Group Limited · NCT03899428TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
EARLY_Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT07242417A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
Phase 1 · 10 location(s) · TORL Biotherapeutics, LLC · NCT06005740At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Phase 1/Phase 2 · 1 location(s) · Shanghai Public Health Clinical Center · NCT03093688A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT06422403Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT04952272GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT05003895Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinom
Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT06558227Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017TARGETed Therapy Drug MONITOring in DIGestive Oncology
NA · 29 location(s) · UNICANCER · NCT05443087FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of P
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07012798Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 6 location(s) · ModeX Therapeutics, An OPKO Health Company · NCT06239194Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab P
Phase 2 · 14 location(s) · National Cancer Centre, Singapore · NCT05377034Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Phase 3 · 32 location(s) · Can-Fite BioPharma · NCT05201404First in Human Study of SIM0610 in Solid Tumors
Phase 1 · 7 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT07348211
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.